<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006122</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06993</org_study_id>
    <secondary_id>EORTC-06993-AML-15</secondary_id>
    <nct_id>NCT00006122</nct_id>
  </id_info>
  <brief_title>Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and
      either kill them or deliver cancer-killing substances to them without harming normal cells.
      Drugs used in chemotherapy uses different ways to stop cancer cells from dividing so they
      stop growing or die. Combining gemtuzumab ozogamicin with chemotherapy may kill more cancer
      cells.

      PURPOSE: Phase II trial to study the effectiveness of gemtuzumab ozogamicin with or without
      chemotherapy in treating older patients who have acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the feasibility, toxicity, and antileukemic activity of gemtuzumab
      ozogamicin (CMA-676) with or without mitoxantrone, etoposide, cytarabine, and idarubicin in
      elderly patients with acute myeloid leukemia.

      OUTLINE: This is a multicenter study. Patients are stratified according to risk (standard
      risk, defined as age 61-75 and WHO performance status 0-1 vs poor risk, defined as over 75
      years and WHO performance status 0-2 OR under 76 years and WHO performance status 2).
      Frontline therapy: Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15.
      Stratum I (Standard risk patients): Patients with disease progression at any time during
      frontline therapy may begin induction therapy immediately. Induction therapy begins 7-10 days
      after response assessment regardless of response and in the absence of unacceptable toxicity.
      Stratum II (Poor risk patients): Patients experiencing complete remission with or without
      platelet recovery will begin consolidation therapy within 4-8 weeks of response assessment in
      the absence of unacceptable toxicity. Stratum I Induction therapy: Patients receive
      mitoxantrone IV over 30 minutes on days 1, 3 and 5; etoposide IV over 1 hour on days 1-3; and
      cytarabine IV continuously on days 1-7. Patients experiencing partial response are given a
      second induction therapy course. Patients experiencing complete remission with or without
      platelet recovery after 1 or 2 induction courses begin consolidation therapy within 4-8 weeks
      of response assessment in the absence of unacceptable toxicity. Consolidation therapy:
      Patients receive idarubicin IV on days 1, 3 and 5; etoposide IV over 1 hour on days 1-3; and
      cytarabine IV continuously on days 1-5. Stratum II Consolidation therapy: Patients receive
      gemtuzumab ozogamicin IV over 2 hours on day 1 and then 1-3 months later. Patients are
      followed monthly for 1 year, every 3 months for 2 years, and then every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 45-82 (28-49 for stratum I, and 17-33 for stratum II) patients
      will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">106</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of primary or secondary acute myeloid leukemia (AML)
        Previously untreated At least 20% marrow blasts AML after myelodysplastic syndrome allowed
        No leukemia after other myeloproliferative diseases No acute promyelocytic leukemia (M3) or
        blastic phase chronic myelogenous leukemia No active CNS leukemia

        PATIENT CHARACTERISTICS: Age: 61 and over Performance status: WHO 0-2 Life expectancy: Not
        specified Hematopoietic: See Disease Characteristics White blood count no greater than
        30,000/mm3 unless reducible to less than 30,000/mm3 by a maximum of 7 days of hydroxyurea
        Hepatic: Bilirubin no greater than 3 times upper limit of normal (ULN) Renal: Creatinine no
        greater than 3 times ULN Cardiovascular: No severe heart failure that would preclude study
        Pulmonary: No severe lung failure that would preclude study Other: No other concurrent
        malignancies No active uncontrolled infection No concurrent severe neurological or
        psychiatric disease No psychological, familial, sociological or geographical condition that
        would preclude compliance with study HIV negative

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior humanized monoclonal antibody therapy
        Chemotherapy: Up to 7 days of prior hydroxyurea allowed At least 24 hours since prior
        hydroxyurea No other prior chemotherapy for AML Endocrine therapy: No more than 7 days of
        prior corticosteroids No other prior endocrine therapy Radiotherapy: No prior radiotherapy
        Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Amadori, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Sant' Eugenio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Z. St. Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <zip>41000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls Universitaet</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto Primo</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groot Ziekengasthuis 's-Hertogenbosch</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M; National Cancer Research Network. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res. 2007 Dec 1;13(23):7059-66.</citation>
    <PMID>18056183</PMID>
  </reference>
  <results_reference>
    <citation>Amadori S, Suciu S, Willemze R, et al.: Up-front window trial of gemtuzumab ozogamicin (GO) in previously untreated elderly patients with AML: an EORTC leukemia group study. [Abstract] Blood 104 (11): A-877, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Amadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R, Ho A, Denzlinger C, Leone G, Fabris P, Muus P, Vignetti M, Hagemeijer A, Beeldens F, Anak O, De Witte T; EORTC leukemia group; GIMEMA leukemia group. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica. 2004 Aug;89(8):950-6.</citation>
    <PMID>15339678</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

